 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Sorivudine" – news ·newspapers ·books ·scholar ·JSTOR(March 2015) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| Trade names | Usevir, Brovavir |
| Other names | BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Metabolism | Viral thymidine kinase |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13BrN2O6 |
| Molar mass | 349.137 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Sorivudine (INN), is anucleoside analogueantiviral drug, marketed under trade names such asUsevir (Nippon Shoji,Eisai) andBrovavir (BMS). It is used for the treatment ofvaricella zoster virus infections.[1]
Sorivudine is active against most species in theherpesvirus family.
Sorivudine interacts strongly and in some cases lethally withfluorouracil (5-FU), itsprodrugs and related substances. This is based on themetabolite bromovinyluracil (BVU), which irreversibly inhibits the enzymedihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drugbrivudine has the same interaction.[2]
Also, it should be taken into consideration that the ability to metabolize this drug can decrease with age due to the composition of thegut microbiota. Specifically, after the age of 60, it has been observed a reduction of the metabolic potential to degrade this compound decreases.[3]
 | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |
